Drugs in Dev.
Infections and Infectious Diseases
IND Enabling
Sweden 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rabeximod
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The IND covers the development of Rabeximod in Covid-19 and other indications, such as rheumatoid arthritis, and is a prerequisite for a future validation of the company’s five recent patent applications in the US market.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 15, 2020
Lead Product(s) : Rabeximod
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rabeximod
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cyxone has received approval from the regulatory authority and the ethics committee in Poland to initiate a Phase 2 clinical trial with Rabeximod in moderate Covid-19 patients.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 08, 2020
Lead Product(s) : Rabeximod
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
